SILVER SPRING
Imfinzi cleared for BCG-naïve high-risk non-muscle-invasive bladder cancer
- Sponsor
- AstraZeneca $AZN
- Drug
- Imfinzi · durvalumab
- Indication
- BCG-naïve, high-risk non-muscle-invasive bladder cancer
FDA approved AstraZeneca's Imfinzi in combination with BCG induction and maintenance therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer.
What this means
Imfinzi (durvalumab) is an immunotherapy drug that helps the immune system recognize and attack bladder cancer cells by blocking a protein called PD-L1. The FDA cleared Imfinzi for use alongside BCG therapy in patients with high-risk bladder cancer who haven’t received BCG treatment before. This approval gives doctors a new option for patients who may need stronger treatment to prevent cancer recurrence.
Drug Watch — recent news on Imfinzi
- Real-World Outcomes With Atezolizumab Plus Bevacizumab vs Durvalumab-Based Therapy - CancerNetwork
- Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC - Oncodaily
- TOPAZ-1 Post Hoc Analysis: Durvalumab Plus GemCis in Advanced Biliary Tract Cancer - Oncodaily
- Yüksel Ürün: EV+Pembrolizumab And GC+Durvalumab Reshape Perioperative MIBC Care - Oncodaily
- PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC - Medscape